Mayne Pharma has acquired a portfolio of marketed dermatology Foam Assets from GSK for $50.1 million. The assets include U.S. rights to Fabior and Sorilux, Canadian rights to Luxiq and Olux-E and Mexican rights to betamethasone foam. Mayne Pharma will acquire the approved regulatory filings, trademarks, marketing materials, select product inventory, and will acquire or obtain licenses for related patents. Fabior Foam, 0.1% is a topical product for the treatment of acne and Sorilux Foam, 0.005...